GH Research (GHRS) News Today → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free GHRS Stock Alerts $12.81 +0.82 (+6.84%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHC Wainwright Weighs in on GH Research PLC's Q2 2024 Earnings (NASDAQ:GHRS)americanbankingnews.com - May 11 at 2:14 AMWall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Knowfinance.yahoo.com - May 10 at 3:45 PMQ2 2024 EPS Estimates for GH Research PLC Reduced by Analyst (NASDAQ:GHRS)marketbeat.com - May 10 at 7:37 AMBuy Rating Affirmed for GH Research Amid Promising Trials and Regulatory Milestonesmarkets.businessinsider.com - May 8 at 9:00 AMGH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwrightamericanbankingnews.com - May 8 at 6:32 AMCanaccord Genuity Group Increases GH Research (NASDAQ:GHRS) Price Target to $31.00americanbankingnews.com - May 8 at 5:36 AMGH Research's (GHRS) "Buy" Rating Reiterated at HC Wainwrightmarketbeat.com - May 7 at 2:35 PMGH Research (NASDAQ:GHRS) Shares Gap Up After Analyst Upgradeamericanbankingnews.com - May 7 at 1:32 AMGH Research (NASDAQ:GHRS) Shares Gap Up Following Analyst Upgrademarketbeat.com - May 6 at 5:33 PMGH Research (NASDAQ:GHRS) Price Target Increased to $31.00 by Analysts at Canaccord Genuity Groupmarketbeat.com - May 6 at 2:45 PMGHRS Stock Earnings: GH Research Beats EPS for Q1 2024investorplace.com - May 3 at 3:18 PMGH Research Reports First Quarter 2024 Financial Results and Provides Business Updatesglobenewswire.com - May 3 at 7:00 AMGH Research PLC (NASDAQ:GHRS) Sees Large Growth in Short Interestmarketbeat.com - May 1 at 6:53 PMGH Research (NASDAQ:GHRS) Shares Up 3.9%marketbeat.com - April 30 at 5:34 PMMGB expands effort to make medical research more sustainablebizjournals.com - April 26 at 2:45 AMGH Video Preview: Gregory in Trouble, Joss Tells Jason She Did Something She Regretsmsn.com - April 26 at 2:45 AMGH Research (NASDAQ:GHRS) Shares Up 6.8%marketbeat.com - April 22 at 5:37 PMGeneral Hospital Video Preview: Is Cyrus the Key to Bringing Down Sonny?yahoo.com - April 18 at 2:38 PMGH Spoilers Weekly Preview Video: It’s Sonny Corinthos Versus the Worldyahoo.com - April 17 at 2:20 PMGH Research (NASDAQ:GHRS) Shares Down 3.1% marketbeat.com - April 17 at 11:58 AMGH Research (NASDAQ:GHRS) Trading Up 2.6%marketbeat.com - April 15 at 5:31 PMGH Research (NASDAQ:GHRS) Trading Down 4.4%marketbeat.com - March 21 at 6:43 PMGH Research (NASDAQ:GHRS) Sees Strong Trading Volumemarketbeat.com - March 20 at 4:31 PMGeneral Hospital Video Preview: Misdirections, Maladies, and Misdiagnosesyahoo.com - March 17 at 8:58 AMGeneral Hospital Video Preview: Catastrophic Thoughts Plague Jason and Sonnyyahoo.com - March 15 at 9:14 AMThe General Hospital Coming Out Storyline Nobody Saw Comingyahoo.com - March 15 at 9:14 AMGH Research (NASDAQ:GHRS) Trading 7.9% Higher marketbeat.com - March 13 at 2:16 PMBuy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advancesmarkets.businessinsider.com - March 4 at 8:36 PMBuy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial Healthmarkets.businessinsider.com - March 1 at 9:58 AMGH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updatesmsn.com - March 1 at 12:07 AMGH Research Reports Full Year 2023 Financial Results and Provides Business Updatesglobenewswire.com - February 29 at 7:00 AMGH Research PLC to Post FY2027 Earnings of ($1.10) Per Share, HC Wainwright Forecasts (NASDAQ:GHRS)marketbeat.com - January 22 at 2:23 AMGH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depressionfinance.yahoo.com - January 18 at 5:17 PMCan GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?finance.yahoo.com - January 16 at 3:04 PMGeneral Hospital Season 61: How Many Episodes & When Do New Episodes Come Out?yahoo.com - January 16 at 10:03 AMGeneral Hospital Season 61 Streaming: Watch & Stream Online via Huluyahoo.com - December 26 at 6:22 PMWe're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wiselyfinance.yahoo.com - December 25 at 9:30 AMThese Four Stocks Tap into the Exploding Psychedelic Treatment Marketnasdaq.com - December 20 at 11:19 PMPsyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And Moremsn.com - November 24 at 1:44 PMAnalysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)markets.businessinsider.com - November 11 at 4:48 AMGH Research Earns ‘Buy’ Rating: Promising Progress, Proactive Approach, and Solid Financial Standingmarkets.businessinsider.com - November 10 at 5:28 PMGH Research PLC: GH Research Reports Third Quarter Financial Results and Provides Business Updatesfinanznachrichten.de - November 10 at 7:27 AMGH Research Reports Third Quarter Financial Results and Provides Business Updatesfinance.yahoo.com - November 9 at 9:27 PMGH Research PLC GHRSmorningstar.com - November 2 at 10:16 AMPositive Outlook for GH Research Despite FDA’s Clinical Hold: An Analysis of GH001’s Trials and Prospectsmarkets.businessinsider.com - October 3 at 3:20 PMGH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Holdbenzinga.com - October 2 at 6:48 PMGH Research PLC: GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depressionfinanznachrichten.de - September 30 at 8:56 AMGH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depressionfinance.yahoo.com - September 29 at 5:28 PMH.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)markets.businessinsider.com - August 24 at 6:06 PMGH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026markets.businessinsider.com - August 24 at 6:06 PM Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… GHRS Media Mentions By Week GHRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GHRS News Sentiment▼0.800.58▲Average Medical News Sentiment GHRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GHRS Articles This Week▼171▲GHRS Articles Average Week Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Olema Pharmaceuticals News Stoke Therapeutics News Calliditas Therapeutics AB (publ) News Zymeworks News Pharming Group News Lyell Immunopharma News ORIC Pharmaceuticals News Castle Biosciences News Phathom Pharmaceuticals News Silence Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GHRS) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap Profits[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
